<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9853761
   </pmid>
   <datecreated>
    <year>
     1999
    </year>
    <month>
     01
    </month>
    <day>
     12
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1999
    </year>
    <month>
     01
    </month>
    <day>
     12
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0306-5456
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       105
      </volume>
      <issue>
       11
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Nov
       </month>
      </pubdate>
     </journalissue>
     <title>
      British journal of obstetrics and gynaecology
     </title>
     <isoabbreviation>
      Br J Obstet Gynaecol
     </isoabbreviation>
    </journal>
    <articletitle>
     The performance of screening tests for ovarian cancer: results of a systematic review.
    </articletitle>
    <pagination>
     <medlinepgn>
      1136-47
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To estimate the performance of currently available tests in detecting ovarian cancer in asymptomatic women.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Systematic review of prospective screening studies.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Twenty-five studies were identified: sixteen studied women at average risk and nine studied women at higher risk. Most studies evaluated only one screening method, were small, detecting few cancers, and gave few follow up details. Sensitivity estimates are therefore imprecise. In a typical larger study, reported sensitivity of ultrasound screening at one year was around 100% (95% CI 54%-100%), while the sensitivity of CA125 measurement followed by ultrasound (multimodal screening) was about 80% (95% CI 49%-95%). False positive rates ranged between 1.2% and 2.5% for grey scale ultrasound, between 0.3% and 0.7% for ultrasound with colour Doppler and between 0.1% and 0.6% for multimodal screening. This implies that, in annual screening of a population with an incidence of 40 per 100,000, and if no cancers were missed, between 2.5 and 60 women would undergo surgery for every primary ovarian cancer detected.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Ultrasound and multimodal screening can detect ovarian cancer in asymptomatic women, but there is currently no evidence on whether screening improves outcome for women in any risk group. On-going randomised controlled trials should establish the magnitude of any benefit of screening. The low prevalence of ovarian cancer in the population, and its rate of progression, may limit the potential cost-effectiveness of screening.
     </abstracttext>
    </abstract>
    <affiliation>
     NHS Centre for Reviews and Dissemination, University of York.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Bell
      </lastname>
      <forename>
       R
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Petticrew
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sheldon
      </lastname>
      <forename>
       T
      </forename>
      <initials>
       T
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Br J Obstet Gynaecol
    </medlineta>
    <nlmuniqueid>
     7503752
    </nlmuniqueid>
    <issnlinking>
     0306-5456
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      CA-125 Antigen
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Br J Obstet Gynaecol. 1999 Oct;106(10):1107-8
     </refsource>
     <pmid version="1">
      10519443
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      CA-125 Antigen
     </descriptorname>
     <qualifiername majortopicyn="Y">
      isolation &amp; purification
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      False Positive Reactions
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Mass Screening
     </descriptorname>
     <qualifiername majortopicyn="Y">
      standards
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ovarian Neoplasms
     </descriptorname>
     <qualifiername majortopicyn="Y">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sensitivity and Specificity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Women's Health
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    50
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9853761
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

